H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases

Core Insights - Altimmune, Inc. (NASDAQ:ALT) is recognized as one of the top 10 stocks under $5 with potential for significant growth [1] - H.C. Wainwright has raised the price target for Altimmune from $12 to $25, maintaining a "Buy" rating, reflecting optimism around the company's pipeline expansion [2] - The focus on the MASH program and the potential of pemvidutide for treating alcohol-related liver disease are highlighted as key drivers for investment [3] Group 1: Company Overview - Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based therapeutics, including pemvidutide for obesity and NASH, and HepTcell for hepatitis B [5] Group 2: Market Outlook - Analysts at B. Riley noted the differentiation of pemvidutide as it enters Phase 3 trials and highlighted a $340 million pro-forma cash runway, which supports a positive outlook for the company [4] - The upcoming Phase 2 RECLAIM AUD topline data expected in Q3 2026 is also a significant factor in the company's future prospects [4]